A groundbreaking new pill could revolutionize the treatment of diabetes and obesity by targeting metabolism directly—with fewer side effects than current therapies. Recent trial results show this innovative medication reduces blood sugar levels and enhances fat burning without causing appetite suppression or muscle wasting, two significant drawbacks of many existing weight loss drugs.
The study, published in the journal Cell, involves researchers from Karolinska Institutet and Stockholm University. Unlike widely prescribed GLP-1 medications such as Wegovy, which require injections and work by altering appetite signals between the gut and brain, this new drug—classified as GRK-biased adrenergic agonists—acts through a completely different mechanism.
Rather than affecting hunger, the experimental drug stimulates skeletal muscle metabolism directly. Animal trials demonstrated improvements in blood sugar regulation and body composition while avoiding typical side effects linked with GLP-1 therapies, including muscle loss, gastrointestinal discomfort, and appetite reduction.
READ MORE: Kate Middleton’s Two Favourite Breakfasts She Enjoys Daily
READ MORE: GP Highlights 6 Common Symptoms to Spot Early Diabetes
Preliminary Phase I clinical trials involving 48 healthy volunteers and 25 people with type 2 diabetes found the treatment to be well tolerated. Tore Bengtsson, professor at Stockholm University’s Department of Molecular Bioscience, commented, “Our results point to a future where we can improve metabolic health without compromising muscle mass. Maintaining muscle is crucial for both managing type 2 diabetes and obesity and is directly linked to longer life expectancy.”
The therapy is based on a specially engineered β2 agonist molecule designed to activate beneficial signaling pathways in muscle tissue while minimizing heart-related side effects—a challenge that has limited previous β2 agonist drugs.
Shane C Wright, assistant professor at Karolinska Institutet, added, “This drug represents an entirely new class of treatment with great potential for type 2 diabetes and obesity patients. Importantly, it encourages healthy weight loss without the need for injections.”
Because this medication works via a mechanism distinct from GLP-1 drugs, it may be effective both on its own and in combination with existing treatments. “This dual potential makes the therapy highly valuable,” Wright said.
Atrogi AB, the pharmaceutical company developing the drug, is preparing to initiate a larger Phase II clinical trial to further evaluate its safety and efficacy.
Researchers are optimistic that the positive results from preclinical studies will translate into meaningful benefits for people with type 2 diabetes or obesity. This new pill differs from recently approved oral semaglutide in the UK, which mimics injected GLP-1 drugs and comes with known side effects.
GLP-1 medications are associated with side effects such as fatigue, dizziness, hair loss, and, in rare cases, acute pancreatitis—a serious condition with symptoms like abdominal pain, fever, nausea, and vomiting. Patients experiencing potential pancreatitis symptoms are advised to seek immediate medical attention.
Common side effects of existing GLP-1 drugs like Wegovy and Mounjaro include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite, among others—highlighting the need for alternative therapies with fewer adverse effects.
Individuals concerned about their weight or diabetes management should consult their healthcare provider for personalized advice.